Natural history of acute upper GI bleeding due to tumours: short‐term success and long‐term recurrence with or without endoscopic therapy

• DOI: 10.1111/apt.12347
• Publication Date: 2013-05-28T09:10:50Z
• Authors: S. Sheibani; J. J. Kim; B. Chen; S. Park; B. Saberi; K. Keyashian; J. Buxbaum; L. Laine
• Keywords: Melena; Upper Gastrointestinal Bleeding

Scant information is available regarding patients with upper gastrointestinal bleeding (UGIB) from tumours.To determine the presentation, endoscopic findings, treatment and outcomes in UGIB malignant tumours identify risk factors associated rebleeding.Consecutive who were hospitalised haematemesis, melena or haematochezia underwent endoscopy identified retrospectively by reviewing an database. Patients due to biopsy-proven studied.Tumours source of 106 (5%) 2,166 UGIB. Tumours oesophageal 17 (16%), gastric 77 (73%) duodenal 12 (11%). At 84 (79%) did not have known cancer previously, 79 (75%) had metastatic disease. Seventy-seven received transfusions at index hospitalisation. endoscopy, 32 (30%) active (31 oozing, 1 spurting). Among actively patients, haemostasis was achieved (86%) 14 receiving therapy all 18 treatment. Hospitalisation for rebleeding occurred 50 (49%) 103 a median 30 days (3-885). On multivariate analysis, age ≤60 years (OR = 2.49, 95% CI 1.06-5.81) haemodynamic instability 2.42, 1.08-5.46) rebleeding.Patients presenting tumour-associated substantial blood loss, three-quarters requiring transfusion presentation. Initial occurs almost without therapy, but repeat hospitalisation approximately half more common are